NetScientific PLC - healthcare IP commercialisation company - Notes portfolio company PDS Biotechnology Corp announced preclinical data for Covid-19 vaccine candidate, Versamune-CoV-2. PDS says vaccine "generated robust preclinical data". Versamune-CoV-2 generated high levels of long-lasting CD8 T-cell responses and potent neutralizing antibody responses within 14 days of vaccination. The study also demonstrated induction of the long-lasting virus-specific memory T-cells necessary for long term protection. Added that preclinical studies showed further substantial increase in neutralising antibody levels continuing more than 30 days after vaccination.
Current stock price: 15.40 pence
Year-to-date change: more than tripled from 4.75 pence.
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Netscientific (NSCI)